VOWST™ (SER-109)
Prevention of recurrent Clostridioides difficile infection (rCDI)
ApprovedCommercial
Key Facts
Indication
Prevention of recurrent Clostridioides difficile infection (rCDI)
Phase
Approved
Status
Commercial
Company
About Seres Therapeutics
Seres Therapeutics is a trailblazer in the microbiome field, with a mission to transform patient lives by restoring microbiome health. Its landmark achievement is the FDA approval and commercialization of VOWST™ for recurrent C. difficile infection, validating its platform and establishing a first-mover advantage. The company's strategy involves leveraging this platform to expand into larger gastrointestinal and immunology indications, while navigating the challenges of commercial execution, pipeline development, and financial sustainability.
View full company profileTherapeutic Areas
Other Prevention of recurrent Clostridioides difficile infection (rCDI) Drugs
| Drug | Company | Phase |
|---|---|---|
| VE303 | Vedanta Biosciences | Phase 3 |